• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

顺二氯二氨合铂(II)在敏感和耐药的人卵巢癌细胞中的积累。

cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

作者信息

Andrews P A, Velury S, Mann S C, Howell S B

机构信息

Cancer Center, University of California, San Diego, La Jolla 92093.

出版信息

Cancer Res. 1988 Jan 1;48(1):68-73.

PMID:3335000
Abstract

We have characterized the accumulation of cisplatin (DDP) into parent and cisplatin-resistant 2008 human ovarian carcinoma cells. Accumulation of DDP at 1 h was a linear function of concentration from 0.25 to 100 microM DDP in both cell types. DDP-resistant cells that were only 3.3-fold resistant had approximately 50% less accumulated platinum at all concentrations examined. Accumulation of 1.0 microM DDP was linear for approximately 3 h and then slowed but did not reach equilibrium at up to 24 h in either cell type. The decreased DDP accumulation in resistant cells did not appear to be due to increased efflux; similar percentages of platinum were available for exodus in parent and resistant cells. Intracellular metabolites of DDP appeared to be decreased by similar amounts in the resistant cells. Native DDP was not driven uphill into cells against a concentration gradient, suggesting that DDP uptake does not involve primary active transport. The metabolic inhibitors, dinitrophenol and NaF, did not decrease DDP accumulation; iodoacetate had a stimulatory effect. Dinitrophenol, however, in combination with NaF or iodoacetate decreased DDP accumulation. A 30-min exposure to 0.2 mM ouabain also decreased DDP accumulation in both parent and resistant cells. A component of DDP accumulation thus appears to be energy dependent. These studies have identified decreased DDP accumulation as an important mechanism of resistance that is expressed early in the acquisition of DDP resistance in human ovarian carcinoma cells.

摘要

我们已经对顺铂(DDP)在亲本及顺铂耐药的2008人卵巢癌细胞中的蓄积情况进行了表征。在两种细胞类型中,1小时时DDP的蓄积是浓度从0.25至100微摩尔/升DDP的线性函数。在所有检测浓度下,仅具有3.3倍耐药性的DDP耐药细胞积累的铂约少50%。1.0微摩尔/升DDP的蓄积在大约3小时内呈线性,然后减慢,但在两种细胞类型中直至24小时都未达到平衡。耐药细胞中DDP蓄积的减少似乎并非由于外排增加;亲本细胞和耐药细胞中可用于外排的铂的百分比相似。DDP的细胞内代谢产物在耐药细胞中的减少量似乎相似。天然DDP不会逆浓度梯度向上转运至细胞内,这表明DDP的摄取不涉及原发性主动转运。代谢抑制剂二硝基苯酚和氟化钠不会降低DDP的蓄积;碘乙酸有刺激作用。然而,二硝基苯酚与氟化钠或碘乙酸联合使用会降低DDP的蓄积。30分钟暴露于0.2毫摩尔/升哇巴因也会降低亲本细胞和耐药细胞中DDP的蓄积。因此,DDP蓄积的一个组成部分似乎是能量依赖性的。这些研究已确定DDP蓄积减少是一种重要的耐药机制,在人卵巢癌细胞获得DDP耐药性的早期就会表现出来。

相似文献

1
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.顺二氯二氨合铂(II)在敏感和耐药的人卵巢癌细胞中的积累。
Cancer Res. 1988 Jan 1;48(1):68-73.
2
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.顺铂和双乙酸-氨-二氯环己胺铂(IV)(JM216)在人卵巢癌细胞系中的转运:一种与顺铂耐药相关的质膜蛋白的鉴定
Clin Cancer Res. 1995 Sep;1(9):981-9.
3
Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells.钠钾-三磷酸腺苷酶在顺二氯二氨铂(II)在人卵巢癌细胞中的蓄积作用。
Cancer Res. 1991 Jul 15;51(14):3677-81.
4
Role of carrier ligand in platinum resistance of human carcinoma cell lines.载体配体在人癌细胞系铂耐药中的作用。
Cancer Res. 1993 Feb 15;53(4):799-805.
5
Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.顺二氯二氨合铂(II)在敏感和耐药人卵巢癌细胞中的脂质含量、表面膜流动性及温度依赖性的比较。
Anticancer Res. 1988 Nov-Dec;8(6):1211-5.
6
Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).在对顺二氯二氨铂(II)耐药的人卵巢癌细胞系中,与DNA结合的铂的清除增加。
Cancer Res. 1990 Mar 15;50(6):1863-6.
7
Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.顺二氯二氨合铂(II)耐药的人卵巢癌细胞中的线粒体缺陷
Cancer Res. 1992 Apr 1;52(7):1895-901.
8
Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.顺铂与锑在人卵巢癌细胞系中的交叉耐药性。
Cancer Res. 1994 Dec 15;54(24):6464-8.
9
Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.通过染料木黄酮调节被动通透性刺激顺二氯二氨铂(II)蓄积:蓄积缺陷型耐药细胞中的改变反应
Clin Cancer Res. 1996 Jun;2(6):991-9.
10
Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.顺二氯二氨合铂(II)对六种哺乳动物细胞系的细胞杀伤作用与顺二氯二氨合铂(II)-DNA抗血清结合之间的相关性。
Cancer Res. 1990 Jun 15;50(12):3556-61.

引用本文的文献

1
Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer.卵巢癌治疗策略中用于检测和靶向微小RNA/表观遗传学的不断演变的格局。
Cancer Lett. 2024 Nov 29;611:217357. doi: 10.1016/j.canlet.2024.217357.
2
In vitro and in vivo accumulation of the anticancer Ru complexes [Ru(cym)(HQ)Cl] and [Ru(cym)(PCA)Cl]Cl.在体和体外积累抗癌 Ru 配合物 [Ru(cym)(HQ)Cl] 和 [Ru(cym)(PCA)Cl]Cl。
J Biol Inorg Chem. 2023 Dec;28(8):767-775. doi: 10.1007/s00775-023-02026-w. Epub 2023 Nov 14.
3
PEGylated nanohydrogels delivering anti-MicroRNA-21 suppress ovarian tumor-associated angiogenesis in matrigel and chicken chorioallantoic membrane models.
递送抗微小RNA-21的聚乙二醇化纳米水凝胶在基质胶和鸡胚绒毛尿囊膜模型中抑制卵巢肿瘤相关血管生成。
Bioimpacts. 2022;12(5):449-461. doi: 10.34172/bi.2022.23263. Epub 2022 Jun 8.
4
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.用于治疗妇科和胃肠道腹膜转移的腹腔内热灌注化疗:一项1期试验的技术和后勤考量
Ann Surg Oncol. 2022 Jan;29(1):175-185. doi: 10.1245/s10434-021-10505-0. Epub 2021 Aug 13.
5
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.靶向ACLY通过抑制PI3K-AKT通路和激活AMPK-ROS通路减弱卵巢癌的肿瘤生长和获得性顺铂耐药性。
Front Oncol. 2021 Mar 17;11:642229. doi: 10.3389/fonc.2021.642229. eCollection 2021.
6
Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy.将金纳米颗粒与其他放射增敏剂相结合以释放癌症放射治疗的全部潜力。
Pharmaceutics. 2021 Mar 25;13(4):442. doi: 10.3390/pharmaceutics13040442.
7
Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.FXYD5 的低表达逆转了上皮性卵巢癌细胞的顺铂耐药性。
Histol Histopathol. 2021 May;36(5):535-545. doi: 10.14670/HH-18-310. Epub 2021 Feb 11.
8
Redox-sensitive, PEG-shielded carboxymethyl PEI nanogels silencing MicroRNA-21, sensitizes resistant ovarian cancer cells to cisplatin.对氧化还原敏感、聚乙二醇屏蔽的羧甲基聚乙烯亚胺纳米凝胶沉默微小RNA-21,使耐药卵巢癌细胞对顺铂敏感。
Asian J Pharm Sci. 2020 Jan;15(1):69-82. doi: 10.1016/j.ajps.2018.10.006. Epub 2018 Dec 1.
9
DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.阿霉素(DOXIL)与印度辣木甾酮A(WFA)联合使用时,可靶向卵巢癌中醛脱氢酶1(ALDH1)阳性的癌症干细胞。
J Cancer Stem Cell Res. 2016;4. doi: 10.14343/JCSCR.2016.4e1002. Epub 2016 Apr 19.
10
Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.Sp1与生存素在上皮性卵巢癌中的关联:Sp1抑制剂与顺铂,一种抑制上皮性卵巢癌细胞增殖的新型联合用药方案
Tumour Biol. 2016 Oct;37(10):14259-14269. doi: 10.1007/s13277-016-5290-9. Epub 2016 Aug 31.